Intercept Pharmaceuticals

👥 501-1000💰 $447,700,000 Post-IPO Debt over 9 years ago🫂 Last layoff over 2 years agoPharmaceuticalBiotechnologyHealth Care📈 Public Company
Website LinkedIn Email Twitter

Intercept Pharmaceuticals is a publicly traded biopharmaceutical company focused on developing and commercializing novel therapeutics for rare and serious liver diseases. We're dedicated to improving the lives of patients with conditions like primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). Our innovative approach to treatment and commitment to patient care positions us as a leader in this critical area of medicine. We maintain a strong presence in the greater New York area. Our tech stack includes ASP.NET, IIS 10, and IIS, supported by Cloudflare for hosting and CDN services. We leverage modern technologies to support our research and development efforts, and foster a collaborative and innovative engineering culture where employees are empowered to make a significant impact. Our commitment to diversity, equity, and inclusion (DEI) enriches the workplace and connects us with the patients and communities we serve. Intercept values a culture of innovation, collaboration, and continuous improvement. We offer comprehensive benefits, including a generous PTO package, 401k matching, and robust health care options, reflecting our commitment to employee well-being. With over 500 employees, we're a dynamic company experiencing substantial growth within the biotech industry. We've successfully raised significant funding, contributing to our capacity for continued advancement in the fight against liver disease. We offer exciting opportunities in a high-impact industry where you can directly contribute to improving the lives of patients suffering from serious liver diseases. Our company operates with a strong sense of purpose, offering employees a challenging and rewarding professional experience.

Related companies: